Evaluation of pregnancy outcomes from the Tysabri® (natalizumab) pregnancy exposure registry: a global, observational, follow-up study
Crossref DOI link: https://doi.org/10.1186/s12883-016-0674-4
Published Online: 2016-08-24
Published Print: 2016-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Friend, Susan
Richman, Sandra
Bloomgren, Gary
Cristiano, Lynda M.
Wenten, Madé
Funding for this research was provided by:
Biogen (US) (Study 101-MS-401)
